MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/md.0000000000049720

Медицинская библиотека · Medicine · 2026

The risk of rash for cancer patients treated with PD-1/PD-L1 inhibitors: An updated systematic review and meta-analysis.

Jiang Qunqun, Liu Junru, Li Zhuoqi, Zhang Chi, Dang Qi, Tian Yuan

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

BACKGROUND

This study was designed to assess the risk of programmed cell death-1 (PD-1) or programmed cell death ligand 1 (PD-L1) related rash in various situations.

METHODS

Guided by Preferred Reporting Items for Systematic Reviews and Meta-Analyses, data on rash in clinical trials related to PD-1 or PD-L1 were collected to comprehensively evaluate its incidence risk in various situations.

RESULTS

Ninety-five clinical trials, divided into 12 groups according to treatment regimens, were enrolled for the final comprehensive assessments and analyses. Compared with chemotherapy or placebo alone, both PD-1 and PD-L1 inhibitors increased the risk of developing rashes for all grades (odds ratio [OR] = 1.61, P = .0003; OR = 2.94, P < .00001). Whether used in combination with chemotherapy or other types of immunosuppressants, similar risk trends were observed (OR = 2.42, P < .00001; OR = 2.11, P = .0007; OR = 4.49, P < .00001; OR = 5.15, P = .0006; OR = 3.16, P = .0002).

CONCLUSION

Both PD-1 and PD-L1 increased the risk of rash occurrence, especially when used in combination with other immunosuppressive antitumor drugs.

Для цитирования: Jiang Qunqun, Liu Junru, Li Zhuoqi, Zhang Chi, Dang Qi, Tian Yuan. The risk of rash for cancer patients treated with PD-1/PD-L1 inhibitors: An updated systematic review and meta-analysis.. Medicine. 2026. DOI: 10.1097/md.0000000000049720.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.